Skip to main content

Arrowhead Pharmaceuticals, Inc.

ARWR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000879407

In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 501 institutions reported holding it in 13F filings for Q2 2026, worth $9.73B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Arrowhead Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $1.19M in total
Insiders trading
2
Net value
−$1.19M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Arrowhead Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Arrowhead Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Olukotun Adeoye YDirector31,600Aug 20, 20263
Perry Michael SDirector111,459Aug 20, 20263
Cohen Matthew GregoryDirector11,882Jun 17, 20261
Lu HongboDirector52,012May 14, 20262
Hamilton James CChief Medical Officer226,958Apr 24, 20265
Apel Daniel JosephChief Financial Officer162,905Apr 24, 20262
O'Brien PatrickCOO547,408Jan 8, 20262
Anzalone Christopher RichardChief Executive Officer3,792,739Jan 5, 20265
Ferrari MauroDirector69,053Dec 30, 20253
Waddill William D.Director56,563Dec 23, 20252
Vakiener VictoriaDirector35,723Dec 23, 20252
Ingram Douglas SDirector46,215Dec 18, 20251
Myszkowski Kenneth AllenChief Financial Officer455,433Jan 7, 20250
Given Douglas BDirector124,167Dec 18, 20240
Oliver TracieChief Commercial Officer127,107Jul 3, 20240
San Martin JavierChief Medical Officer198,497Jan 8, 20240
De Backer MarianneDirector31,267Jan 11, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 10, 2021 (view filing)Sep 91 dayGiven Douglas BDirectorSSale−5.00K$65.24−$326.2K−4.4%109.9K after
Sep 14, 2021 (view filing)Sep 131 dayOlukotun Adeoye YDirectorSSale−5.00K$63.76−$318.8K−35.7%9.00K after2 lots
Oct 22, 2021 (view filing)Oct 20-222 daysAnzalone Christopher RichardChief Executive OfficerSSale−65.0K$65.77−$4.27M−1.9%3.28M after3 lots
Nov 22, 2021 (view filing)Nov 193 daysSan Martin JavierChief Medical OfficerSSale−19.5K$69.31−$1.35M−14.9%111.0K after3 lots
Dec 17, 2021 (view filing)Dec 152 daysAnzalone Christopher RichardChief Executive OfficerSSale−60.0K$67.56−$4.05M−1.8%3.22M after5 lots
Dec 29, 2021 (view filing)Dec 281 dayFerrari MauroDirectorSSale−3.40K$66.82−$227.2K−8.5%36.6K after
Dec 29, 2021 (view filing)Dec 281 dayGiven Douglas BDirectorPPurchase+655$66.37+$43.5K+0.6%109.9K after
Jan 4, 2022 (view filing)Jan 31 dayPerry Michael SDirectorSSale−4.50K$64.71−$291.2K−5.0%85.5K after3 lots
Jan 4, 2022 (view filing)Jan 31 dayDe Backer MarianneDirectorSSale−4.50K$64.71−$291.2K−20.9%17.0K after3 lots
Jan 4, 2022 (view filing)Jan 31 dayOlukotun Adeoye YDirectorSSale−4.05K$64.75−$262.2K−45.0%4.95K after3 lots
Jan 4, 2022 (view filing)Jan 31 dayWaddill William D.DirectorSSale−4.50K$64.72−$291.2K−14.9%25.8K after3 lots
Jan 6, 2022 (view filing)Jan 4-52 daysHamilton James COther: Senior Vice PresidentSSale−25.6K$64.57−$1.65M−14.1%155.6K after10 lots
Jan 6, 2022 (view filing)Jan 51 dayMyszkowski Kenneth AllenChief Financial OfficerSSale−40.0K$61.70−$2.47M−7.9%464.0K after4 lots
Jan 7, 2022 (view filing)Jan 52 daysO'Brien PatrickGeneral CounselSSale−32.5K$61.72−$2.01M−8.5%348.9K after5 lots
Feb 14, 2022 (view filing)Feb 113 daysAnzalone Christopher RichardChief Executive OfficerSSale−146.4K$51.91−$7.60M−3.5%4.06M after4 lots
Nov 22, 2022 (view filing)Nov 211 daySan Martin JavierChief Medical OfficerSSale−19.5K$29.99−$584.7K−17.6%91.5K after2 lots
Dec 30, 2022 (view filing)Dec 291 dayMyszkowski Kenneth AllenChief Financial OfficerSSale−30.6K$40.00−$1.23M−8.3%336.7K after
Jan 5, 2023 (view filing)Jan 32 daysHamilton James COther: Chief Discovery/Trans MedicineSSale−10.3K$38.38−$396.7K−6.6%145.3K after8 lots
Jan 5, 2023 (view filing)Jan 32 daysO'Brien PatrickCOO and General CounselSSale−17.5K$38.33−$670.8K−4.6%363.4K after8 lots
Jan 6, 2023 (view filing)Jan 51 dayHamilton James COther: Chief Discovery/Trans MedicineSSale−13.8K$37.40−$516.2K−6.7%191.5K after2 lots
Jan 6, 2023 (view filing)Jan 51 dayO'Brien PatrickCOO and General CounselSSale−15.0K$37.39−$560.9K−3.5%413.4K after2 lots
Jan 11, 2023 (view filing)Jan 92 daysWaddill William D.DirectorSSale−3.20K$30.00−$96.0K−10.0%28.9K after
Mar 1, 2023 (view filing)Feb 272 daysGiven Douglas BDirectorSSale−875$32.62−$28.5K−6.3%13.0K after
Mar 6, 2023 (view filing)Mar 33 daysOlukotun Adeoye YDirectorSSale−11.3K$32.65−$370.6K−59.1%7.87K after
May 5, 2023 (view filing)May 3-42 daysAnzalone Christopher RichardChief Executive OfficerSSale−104.9K$39.32−$4.13M−2.7%3.76M after3 lots
May 8, 2023 (view filing)May 53 daysGiven Douglas BDirectorSSale−6.50K$40.90−$265.9K−5.2%117.6K after
Jun 29, 2023 (view filing)Jun 272 daysMyszkowski Kenneth AllenChief Financial OfficerSSale−15.0K$36.20−$543.0K−3.8%381.7K after
Jul 5, 2023 (view filing)Jun 305 daysHamilton James COther: Chief Discovery/Trans MedicineSSale−3.00K$35.53−$106.6K−1.6%188.5K after
Jul 6, 2023 (view filing)Jul 33 daysOliver TracieChief Commercial OfficerSSale−8.93K$35.31−$315.1K−12.7%61.6K after
Sep 20, 2023 (view filing)Sep 182 daysAnzalone Christopher RichardChief Executive OfficerSSale−57.8K$28.12−$1.62M−1.5%3.76M after2 lots
Oct 2, 2023 (view filing)Sep 284 daysVakiener VictoriaDirectorSSale−1.55K$26.33−$40.8K−6.7%21.7K after
Oct 27, 2023 (view filing)Oct 252 daysAnzalone Christopher RichardChief Executive OfficerSSale−24.3K$24.21−$589.2K−0.6%3.74M after10b5-1
Nov 22, 2023 (view filing)Nov 202 daysSan Martin JavierChief Medical OfficerSSale−19.7K$28.80−$567.3K−13.0%131.8K after2 lots10b5-1
Dec 22, 2023 (view filing)Dec 202 daysAnzalone Christopher RichardChief Executive OfficerSSale−12.0K$28.54−$342.5K−0.3%3.73M after10b5-1
Jan 4, 2024 (view filing)Jan 22 daysAnzalone Christopher RichardChief Executive OfficerSSale−9.95K$31.01−$308.6K−0.3%3.72M after2 lots10b5-1
Jan 5, 2024 (view filing)Jan 3-52 daysO'Brien PatrickCOO and General CounselSSale−33.2K$34.36−$1.14M−6.7%464.4K after8 lots10b5-1
Jan 5, 2024 (view filing)Jan 3-52 daysHamilton James COther: Chief Discovery/Trans MedicineSSale−38.4K$34.69−$1.33M−14.9%218.8K after7 lots10b5-1
Jan 8, 2024 (view filing)Jan 53 daysSan Martin JavierChief Medical OfficerSSale−8.30K$35.26−$292.8K−4.0%198.5K after3 lots10b5-1
Jan 8, 2024 (view filing)Jan 53 daysMyszkowski Kenneth AllenChief Financial OfficerSSale−16.1K$35.27−$567.9K−3.5%440.6K after3 lots10b5-1
Jan 8, 2024 (view filing)Jan 53 daysOliver TracieChief Commercial OfficerSSale−74$33.89−$2.51K−0.1%136.5K after10b5-1
Jan 16, 2024 (view filing)Jan 115 daysVakiener VictoriaDirectorSSale−4.72K$38.10−$179.8K−12.9%32.0K after2 lots10b5-1
Jan 16, 2024 (view filing)Jan 115 daysFerrari MauroDirectorSSale−3.15K$38.06−$119.8K−4.9%60.8K after2 lots10b5-1
Jan 16, 2024 (view filing)Jan 115 daysWaddill William D.DirectorSSale−3.93K$38.07−$149.8K−7.6%47.9K after2 lots10b5-1
Jan 16, 2024 (view filing)Jan 115 daysGiven Douglas BDirectorSSale−2.91K$38.06−$110.8K−2.2%129.7K after2 lots10b5-1
Jan 17, 2024 (view filing)Jan 125 daysHamilton James CChief Discovery/Trans MedicineSSale−7.94K$36.89−$292.9K−3.6%210.9K after2 lots10b5-1
Feb 2, 2024 (view filing)Jan 312 daysAnzalone Christopher RichardChief Executive OfficerSSale−57.5K$32.35−$1.86M−1.5%3.72M after2 lots10b5-1
Mar 8, 2024 (view filing)Mar 62 daysMyszkowski Kenneth AllenChief Financial OfficerSSale−40.0K$35.19−$1.41M−9.1%400.6K after
Mar 20, 2024 (view filing)Mar 18-202 daysLu HongboDirectorPPurchase+3.00K$27.66+$83.0K+9.8%33.7K after3 lots
Apr 3, 2024 (view filing)Apr 12 daysHamilton James CChief Discovery/Trans MedicineSSale−6.00K$28.03−$168.2K−2.8%204.9K after
May 6, 2024 (view filing)May 24 daysVakiener VictoriaDirectorSSale−1.80K$23.31−$41.9K−5.6%30.2K after10b5-1